Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

NCT06186037 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

6356

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease
Dyslipidemias
Primary Prevention

Interventions

DRUG: Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mg
DRUG: Mono drug group of Rosuvastatin 20 mg

Sponsor

Saint Vincent's Hospital, Korea